Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Eledon Pharmaceuticals in a report issued on Wednesday, June 18th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.32) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Eledon Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.27) EPS.
Separately, Wall Street Zen cut Eledon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, June 6th.
Eledon Pharmaceuticals Stock Performance
NASDAQ:ELDN opened at $2.72 on Thursday. The stock has a fifty day moving average price of $3.04 and a two-hundred day moving average price of $3.70. The stock has a market capitalization of $162.87 million, a price-to-earnings ratio of -1.30 and a beta of -0.17. Eledon Pharmaceuticals has a 1 year low of $2.30 and a 1 year high of $5.54.
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.20.
Hedge Funds Weigh In On Eledon Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its stake in shares of Eledon Pharmaceuticals by 418.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after purchasing an additional 6,412 shares in the last quarter. CW Advisors LLC acquired a new position in shares of Eledon Pharmaceuticals in the 1st quarter valued at about $34,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Eledon Pharmaceuticals in the 1st quarter valued at about $41,000. Alpine Global Management LLC acquired a new position in shares of Eledon Pharmaceuticals in the 4th quarter valued at about $56,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Eledon Pharmaceuticals in the 4th quarter valued at about $66,000. 56.77% of the stock is owned by institutional investors and hedge funds.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Articles
- Five stocks we like better than Eledon Pharmaceuticals
- Canada Bond Market Holiday: How to Invest and Trade
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Overheated Market? Analysts Watch These Red Flags
- How to Calculate Return on Investment (ROI)
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.